BioNTech Restructures: Founders Take the Reins of a New mRNA Venture as the Core Company Pushes Toward a 2026 Cancer Filing

BioNTech is remaking itself on two fronts at once. While the company’s founders prepare to spin out the next generation of messenger-RNA research into a separate entity, the core business is charging toward its first oncology approval with a regulatory filing planned for 2026. The twin moves mark the most radical overhaul since the pandemic windfall.

By the end of June, the Mainz-based developer will transfer select mRNA assets and rights to a new biotechnology company led by co-founders Ugur Sahin and Özlem Türeci. BioNTech will retain a minority stake in the spin-off, which will focus entirely on next-generation mRNA technologies and operate with its own resources. The move frees the parent company to concentrate exclusively on commercialising its late-stage cancer pipeline without distraction.

That pipeline now centres on the antibody-drug conjugate Trastuzumab Pamirtecan, which is being developed with partner DualityBio for advanced endometrial cancer. BioNTech intends to submit a marketing application in 2026, subject to feedback from the U.S. Food and Drug Administration. The data set is based on Phase 2 trials, an approach that carries extra regulatory risk. A green light would be a historic milestone; a request for further data could push the timeline into 2027.

The oncology push gained momentum this spring. At the American Society of Clinical Oncology conference, BioNTech presented encouraging data from several programmes, prompting UBS to raise its rating on the shares to Buy with a $135 price target. The ROSETTA Lung-02 study showed that the candidate Pumitamig, one of the company’s lead antibodies, delivered strong response rates in lung cancer. Another agent, Gotistobart, also generated positive early signals.

Should investors sell immediately? Or is it worth buying BioNTech?

Analyst sentiment is broadly positive, with the consensus target hovering near $130. Yet the stock has struggled to reflect that optimism. On Friday it closed at €79.95, roughly six percent below its 200-day moving average and far from the 52-week high of €105.80. Earlier in the week it traded as low as €78.75, leaving it about eight percent under the same long-term trend line. The relative strength index sits at 54.2, a neutral reading that suggests the equity is coiled for a move in either direction.

The company’s financial position provides ample cover for the ambitious clinical plan. Liquid assets stood at roughly €16.8 billion at the end of March, a war chest that eliminates any near-term dilution risk. That cash pile will soon be split between the parent and the new mRNA venture, with details still to be clarified in the coming weeks.

Revenue has collapsed as the Covid vaccine business fades. First-quarter sales tumbled to €118.1 million, and BioNTech reported a net loss of nearly €532 million. Management forecasts full-year revenue of €2.0 billion to €2.3 billion, below market expectations. Research and development spending is expected to reach as much as €2.5 billion this year.

To offset the burn, the company is slashing annual costs by roughly €500 million. It is shuttering facilities in Germany and Singapore and eliminating almost 1,900 positions. The goal is a leaner cost structure that can sustain the oncology push without further capital raises.

BioNTech at a turning point? This analysis reveals what investors need to know now.

BioNTech plans to launch six additional Phase 3 studies this year, bringing its late-stage clinical programme to 15 trials by the end of 2026. Seven major data readouts are scheduled for the second half of the current year, and next quarter’s results in early August should offer early clues on whether the pipeline is on track to deliver the first oncology sales.

The transformation is not without risk. The FDA applies especially strict standards when evaluating Phase 2 data for an accelerated filing. And the market has yet to reward BioNTech’s strategic pivot — the shares remain well below their 50-day line of €80.81, a level that has acted as resistance in recent sessions. For the bulls, the combination of a fully funded pipeline, a restructuring that sharpens focus, and a potential blockbuster filing in 2026 represents an inflection point. For the bears, the high R&D spending, uncertain regulatory path, and lack of near-term revenue visibility argue for patience. Either way, the next few months will determine which camp is right.

Ad

BioNTech Stock: New Analysis - 27 June

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69636537 |